 Irina Petrache
Concepts (584)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pulmonary Emphysema | 34 | 2023 | 265 | 9.540 |
Why?
| | Ceramides | 23 | 2023 | 91 | 5.330 |
Why?
| | alpha 1-Antitrypsin | 15 | 2023 | 101 | 5.250 |
Why?
| | Lung | 53 | 2023 | 3497 | 4.760 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 23 | 2023 | 902 | 4.510 |
Why?
| | Endothelial Cells | 24 | 2023 | 677 | 4.320 |
Why?
| | Smoking | 30 | 2020 | 1380 | 4.190 |
Why?
| | Apoptosis | 38 | 2020 | 2288 | 3.700 |
Why?
| | Cigarette Smoking | 8 | 2022 | 73 | 3.590 |
Why?
| | Lung Injury | 11 | 2023 | 192 | 3.570 |
Why?
| | Smoke | 12 | 2021 | 122 | 3.200 |
Why?
| | Electronic Nicotine Delivery Systems | 7 | 2023 | 71 | 3.030 |
Why?
| | Emphysema | 10 | 2023 | 105 | 2.540 |
Why?
| | Sphingolipids | 7 | 2018 | 57 | 2.310 |
Why?
| | alpha 1-Antitrypsin Deficiency | 8 | 2019 | 69 | 2.230 |
Why?
| | Pulmonary Alveoli | 15 | 2018 | 369 | 2.200 |
Why?
| | Macrophages, Alveolar | 5 | 2021 | 341 | 2.180 |
Why?
| | Vaping | 3 | 2023 | 45 | 1.650 |
Why?
| | Sphingomyelin Phosphodiesterase | 6 | 2023 | 21 | 1.550 |
Why?
| | Animals | 86 | 2023 | 31162 | 1.490 |
Why?
| | Endothelium, Vascular | 11 | 2023 | 829 | 1.470 |
Why?
| | Tobacco Products | 5 | 2021 | 96 | 1.440 |
Why?
| | Mice | 56 | 2023 | 14679 | 1.420 |
Why?
| | Microvessels | 4 | 2021 | 66 | 1.410 |
Why?
| | Hypertension, Pulmonary | 8 | 2022 | 1733 | 1.350 |
Why?
| | Signal Transduction | 19 | 2020 | 4439 | 1.350 |
Why?
| | Oxidative Stress | 13 | 2020 | 1065 | 1.310 |
Why?
| | Cells, Cultured | 23 | 2021 | 3802 | 1.250 |
Why?
| | Autophagy | 7 | 2021 | 235 | 1.240 |
Why?
| | Tumor Necrosis Factor-alpha | 6 | 2017 | 1106 | 1.210 |
Why?
| | Disease Models, Animal | 16 | 2022 | 3470 | 1.210 |
Why?
| | Acute Lung Injury | 3 | 2021 | 266 | 1.190 |
Why?
| | Mice, Inbred C57BL | 27 | 2022 | 4617 | 1.190 |
Why?
| | Alveolar Epithelial Cells | 3 | 2018 | 93 | 1.170 |
Why?
| | Pneumonia | 5 | 2021 | 561 | 1.100 |
Why?
| | Hypoxia | 6 | 2020 | 919 | 1.050 |
Why?
| | Caspase 3 | 7 | 2016 | 227 | 1.030 |
Why?
| | Receptors, Estrogen | 3 | 2014 | 371 | 1.030 |
Why?
| | Membrane Proteins | 5 | 2022 | 1008 | 1.020 |
Why?
| | Pulmonary Artery | 10 | 2022 | 1012 | 1.020 |
Why?
| | Adipose Tissue | 5 | 2017 | 537 | 0.990 |
Why?
| | MicroRNAs | 2 | 2022 | 598 | 0.980 |
Why?
| | Humans | 98 | 2024 | 113531 | 0.970 |
Why?
| | Rats | 22 | 2017 | 4829 | 0.970 |
Why?
| | Tobacco Smoke Pollution | 4 | 2018 | 218 | 0.920 |
Why?
| | Up-Regulation | 10 | 2020 | 794 | 0.920 |
Why?
| | Neovascularization, Physiologic | 3 | 2020 | 174 | 0.910 |
Why?
| | Endothelium | 4 | 2023 | 109 | 0.910 |
Why?
| | Endocytosis | 3 | 2016 | 143 | 0.910 |
Why?
| | Vascular System Injuries | 1 | 2023 | 66 | 0.800 |
Why?
| | Rats, Sprague-Dawley | 14 | 2018 | 2139 | 0.750 |
Why?
| | Phagocytosis | 3 | 2021 | 335 | 0.750 |
Why?
| | Niemann-Pick Disease, Type A | 1 | 2021 | 4 | 0.740 |
Why?
| | Niemann-Pick Disease, Type B | 1 | 2021 | 4 | 0.740 |
Why?
| | Lysophospholipase | 1 | 2021 | 10 | 0.740 |
Why?
| | Large Neutral Amino Acid-Transporter 1 | 1 | 2020 | 15 | 0.690 |
Why?
| | Translocation, Genetic | 1 | 2020 | 92 | 0.680 |
Why?
| | Macrophages | 4 | 2021 | 1233 | 0.680 |
Why?
| | Hyaluronic Acid | 2 | 2020 | 189 | 0.680 |
Why?
| | Immunoglobulins | 1 | 2020 | 141 | 0.670 |
Why?
| | Epithelial Cells | 10 | 2022 | 939 | 0.670 |
Why?
| | Glucosylceramides | 1 | 2019 | 7 | 0.670 |
Why?
| | Mice, Knockout | 11 | 2021 | 2523 | 0.670 |
Why?
| | Estradiol | 3 | 2018 | 450 | 0.660 |
Why?
| | Glycoproteins | 1 | 2021 | 302 | 0.650 |
Why?
| | Enzyme Inhibitors | 4 | 2018 | 737 | 0.640 |
Why?
| | Influenza, Human | 2 | 2022 | 543 | 0.640 |
Why?
| | Antibodies, Neutralizing | 2 | 2019 | 222 | 0.630 |
Why?
| | Complement Pathway, Mannose-Binding Lectin | 1 | 2019 | 21 | 0.630 |
Why?
| | Lysosomes | 2 | 2021 | 123 | 0.610 |
Why?
| | Alpha-Globulins | 1 | 2018 | 20 | 0.600 |
Why?
| | RNA-Binding Proteins | 5 | 2019 | 342 | 0.600 |
Why?
| | Neoplasm Proteins | 5 | 2019 | 381 | 0.600 |
Why?
| | Sphingosine | 5 | 2015 | 33 | 0.600 |
Why?
| | Heterocyclic Compounds | 1 | 2018 | 18 | 0.600 |
Why?
| | Xeroderma Pigmentosum | 1 | 2018 | 7 | 0.600 |
Why?
| | Bronchoalveolar Lavage Fluid | 7 | 2018 | 578 | 0.590 |
Why?
| | Metformin | 1 | 2021 | 273 | 0.590 |
Why?
| | Oncostatin M | 1 | 2017 | 6 | 0.580 |
Why?
| | Sphingosine N-Acyltransferase | 2 | 2018 | 4 | 0.580 |
Why?
| | Thorax | 2 | 2022 | 40 | 0.570 |
Why?
| | Cell Movement | 4 | 2020 | 852 | 0.550 |
Why?
| | Cell Death | 4 | 2019 | 320 | 0.540 |
Why?
| | Multiprotein Complexes | 1 | 2018 | 140 | 0.540 |
Why?
| | Male | 43 | 2022 | 55112 | 0.530 |
Why?
| | DNA Repair | 1 | 2018 | 182 | 0.530 |
Why?
| | Genetic Predisposition to Disease | 3 | 2020 | 2077 | 0.510 |
Why?
| | DNA Damage | 1 | 2018 | 345 | 0.500 |
Why?
| | Cell-Derived Microparticles | 1 | 2016 | 54 | 0.500 |
Why?
| | Cytokines | 9 | 2019 | 1795 | 0.500 |
Why?
| | Scavenger Receptors, Class B | 1 | 2015 | 8 | 0.500 |
Why?
| | Telemetry | 1 | 2015 | 35 | 0.490 |
Why?
| | Mice, Transgenic | 8 | 2022 | 1925 | 0.480 |
Why?
| | Cosmic Radiation | 1 | 2014 | 4 | 0.480 |
Why?
| | ADAM Proteins | 3 | 2022 | 58 | 0.480 |
Why?
| | Female | 34 | 2022 | 59115 | 0.470 |
Why?
| | Blood Pressure Monitoring, Ambulatory | 1 | 2015 | 61 | 0.470 |
Why?
| | Oxidoreductases | 4 | 2011 | 89 | 0.460 |
Why?
| | Cell Proliferation | 9 | 2020 | 2164 | 0.460 |
Why?
| | Transcytosis | 1 | 2014 | 8 | 0.460 |
Why?
| | Lung Diseases | 3 | 2017 | 688 | 0.460 |
Why?
| | Alginates | 1 | 2014 | 43 | 0.460 |
Why?
| | Gene Expression Regulation, Enzymologic | 2 | 2013 | 270 | 0.450 |
Why?
| | Palmitic Acids | 1 | 2014 | 9 | 0.450 |
Why?
| | Receptors, Lysosphingolipid | 2 | 2014 | 12 | 0.450 |
Why?
| | Thoracic Vertebrae | 1 | 2014 | 67 | 0.450 |
Why?
| | Inflammation | 7 | 2023 | 2444 | 0.450 |
Why?
| | Nicotinic Agonists | 1 | 2015 | 100 | 0.450 |
Why?
| | Caspase Inhibitors | 3 | 2011 | 76 | 0.440 |
Why?
| | Enzyme Activation | 8 | 2015 | 752 | 0.440 |
Why?
| | Spinal Injuries | 1 | 2014 | 47 | 0.440 |
Why?
| | Stem Cell Transplantation | 2 | 2015 | 144 | 0.440 |
Why?
| | Tracheostomy | 1 | 2014 | 97 | 0.420 |
Why?
| | Interleukin-6 | 1 | 2016 | 661 | 0.420 |
Why?
| | Trypsin Inhibitors | 2 | 2017 | 5 | 0.410 |
Why?
| | Lysophospholipids | 5 | 2015 | 60 | 0.410 |
Why?
| | Pseudomonas Infections | 1 | 2014 | 183 | 0.410 |
Why?
| | Nicotine | 1 | 2015 | 263 | 0.410 |
Why?
| | Cystic Fibrosis | 2 | 2014 | 953 | 0.410 |
Why?
| | Metabolomics | 5 | 2018 | 508 | 0.400 |
Why?
| | Pseudomonas aeruginosa | 1 | 2014 | 297 | 0.390 |
Why?
| | Estrogens | 1 | 2014 | 311 | 0.380 |
Why?
| | Exercise Therapy | 1 | 2015 | 351 | 0.380 |
Why?
| | Cell Differentiation | 2 | 2018 | 1681 | 0.370 |
Why?
| | Photons | 1 | 2011 | 57 | 0.360 |
Why?
| | Tumor Suppressor Proteins | 1 | 2013 | 283 | 0.360 |
Why?
| | Stress, Physiological | 1 | 2014 | 375 | 0.360 |
Why?
| | Peptidyl-Dipeptidase A | 2 | 2021 | 51 | 0.360 |
Why?
| | Hemodynamics | 1 | 2015 | 996 | 0.360 |
Why?
| | Virus Diseases | 2 | 2023 | 192 | 0.350 |
Why?
| | Adult Stem Cells | 1 | 2010 | 32 | 0.350 |
Why?
| | Dose-Response Relationship, Drug | 6 | 2014 | 1822 | 0.340 |
Why?
| | Pancreatic Elastase | 2 | 2021 | 55 | 0.330 |
Why?
| | Phenotype | 7 | 2020 | 2754 | 0.330 |
Why?
| | Caspases | 3 | 2011 | 236 | 0.330 |
Why?
| | TOR Serine-Threonine Kinases | 3 | 2021 | 357 | 0.320 |
Why?
| | Superoxide Dismutase | 3 | 2020 | 302 | 0.320 |
Why?
| | Diagnostic Imaging | 1 | 2011 | 278 | 0.310 |
Why?
| | Fingolimod Hydrochloride | 3 | 2022 | 29 | 0.310 |
Why?
| | DNA-Binding Proteins | 2 | 2012 | 1286 | 0.290 |
Why?
| | Biomarkers | 8 | 2021 | 3389 | 0.290 |
Why?
| | Transcription Factors | 2 | 2012 | 1497 | 0.290 |
Why?
| | Mass Spectrometry | 4 | 2018 | 616 | 0.290 |
Why?
| | Hydrogen-Ion Concentration | 1 | 2009 | 502 | 0.290 |
Why?
| | Fibrinolysin | 1 | 2007 | 11 | 0.280 |
Why?
| | Heart | 1 | 2011 | 609 | 0.280 |
Why?
| | Lipopolysaccharides | 4 | 2023 | 802 | 0.280 |
Why?
| | Hypertrophy, Right Ventricular | 3 | 2016 | 140 | 0.270 |
Why?
| | RNA, Small Interfering | 3 | 2018 | 528 | 0.270 |
Why?
| | Thrombin | 1 | 2007 | 129 | 0.270 |
Why?
| | Electric Impedance | 3 | 2015 | 96 | 0.260 |
Why?
| | Gene Expression Regulation | 5 | 2020 | 2293 | 0.260 |
Why?
| | Vascular Remodeling | 3 | 2022 | 152 | 0.260 |
Why?
| | Receptors, Vascular Endothelial Growth Factor | 4 | 2012 | 103 | 0.260 |
Why?
| | Cystic Fibrosis Transmembrane Conductance Regulator | 1 | 2009 | 287 | 0.250 |
Why?
| | ADAM17 Protein | 2 | 2017 | 30 | 0.250 |
Why?
| | Mice, Inbred DBA | 2 | 2019 | 172 | 0.250 |
Why?
| | Leukocytes | 3 | 2022 | 268 | 0.250 |
Why?
| | Tomography, X-Ray Computed | 1 | 2014 | 2269 | 0.240 |
Why?
| | Cell Adhesion | 2 | 2020 | 423 | 0.240 |
Why?
| | Gas Chromatography-Mass Spectrometry | 2 | 2015 | 118 | 0.230 |
Why?
| | Caspase 6 | 2 | 2016 | 3 | 0.230 |
Why?
| | Caspase 7 | 2 | 2016 | 20 | 0.230 |
Why?
| | Recombinant Fusion Proteins | 2 | 2021 | 599 | 0.230 |
Why?
| | Middle Aged | 11 | 2022 | 26552 | 0.230 |
Why?
| | Homeostasis | 3 | 2018 | 561 | 0.220 |
Why?
| | Chemokine CX3CL1 | 1 | 2023 | 21 | 0.220 |
Why?
| | Capillary Permeability | 2 | 2015 | 134 | 0.220 |
Why?
| | Cell Culture Techniques | 2 | 2019 | 337 | 0.210 |
Why?
| | Biomedical Technology | 1 | 2024 | 39 | 0.210 |
Why?
| | Monocytes | 4 | 2023 | 499 | 0.210 |
Why?
| | Receptors, CXCR3 | 2 | 2013 | 15 | 0.210 |
Why?
| | Pulmonary Medicine | 1 | 2024 | 69 | 0.210 |
Why?
| | Myosin-Light-Chain Kinase | 1 | 2003 | 19 | 0.210 |
Why?
| | Cell Line | 4 | 2017 | 2581 | 0.210 |
Why?
| | rho GTP-Binding Proteins | 1 | 2003 | 59 | 0.210 |
Why?
| | Oxygen Consumption | 2 | 2022 | 568 | 0.200 |
Why?
| | Cell Adhesion Molecules | 2 | 2015 | 160 | 0.200 |
Why?
| | X-Ray Microtomography | 2 | 2022 | 73 | 0.190 |
Why?
| | Mice, Inbred BALB C | 3 | 2018 | 1136 | 0.190 |
Why?
| | Primary Cell Culture | 2 | 2013 | 148 | 0.190 |
Why?
| | Flow Cytometry | 4 | 2015 | 1065 | 0.190 |
Why?
| | Dronabinol | 1 | 2023 | 118 | 0.190 |
Why?
| | Societies, Medical | 2 | 2023 | 654 | 0.190 |
Why?
| | Congresses as Topic | 1 | 2023 | 194 | 0.190 |
Why?
| | Influenza A virus | 1 | 2022 | 90 | 0.190 |
Why?
| | beta-N-Acetylhexosaminidases | 1 | 2021 | 9 | 0.190 |
Why?
| | Th1-Th2 Balance | 1 | 2021 | 9 | 0.190 |
Why?
| | Chitinases | 1 | 2021 | 8 | 0.190 |
Why?
| | Immunoglobulin Fc Fragments | 1 | 2021 | 35 | 0.180 |
Why?
| | Cytoskeleton | 3 | 2011 | 163 | 0.180 |
Why?
| | CD11 Antigens | 1 | 2021 | 27 | 0.180 |
Why?
| | Lectins | 1 | 2021 | 39 | 0.180 |
Why?
| | Cell Size | 1 | 2021 | 79 | 0.180 |
Why?
| | CD11b Antigen | 1 | 2021 | 56 | 0.180 |
Why?
| | Kinetics | 3 | 2015 | 1528 | 0.180 |
Why?
| | Microtubules | 1 | 2003 | 234 | 0.180 |
Why?
| | Hypoxia-Inducible Factor 1, alpha Subunit | 2 | 2022 | 248 | 0.180 |
Why?
| | Protein Inhibitors of Activated STAT | 1 | 2020 | 6 | 0.180 |
Why?
| | Inhalation Exposure | 1 | 2021 | 95 | 0.180 |
Why?
| | Endothelial Progenitor Cells | 1 | 2020 | 17 | 0.180 |
Why?
| | Blotting, Western | 4 | 2011 | 1128 | 0.180 |
Why?
| | Chromosomes, Human, Pair 4 | 1 | 2020 | 28 | 0.180 |
Why?
| | Integrin beta1 | 1 | 2020 | 17 | 0.180 |
Why?
| | Sirolimus | 1 | 2021 | 181 | 0.180 |
Why?
| | Stem Cell Niche | 1 | 2020 | 41 | 0.170 |
Why?
| | Receptors, CXCR4 | 2 | 2018 | 78 | 0.170 |
Why?
| | Chromosomes, Human, Pair 1 | 1 | 2020 | 66 | 0.170 |
Why?
| | Lactic Acid | 1 | 2022 | 269 | 0.170 |
Why?
| | Kruppel-Like Transcription Factors | 1 | 2020 | 61 | 0.170 |
Why?
| | Ischemia | 2 | 2018 | 357 | 0.170 |
Why?
| | Tobacco Smoking | 1 | 2020 | 21 | 0.170 |
Why?
| | Stromal Cells | 2 | 2017 | 95 | 0.170 |
Why?
| | Cell Membrane | 3 | 2013 | 663 | 0.170 |
Why?
| | Case-Control Studies | 2 | 2017 | 2993 | 0.170 |
Why?
| | Oxidants | 2 | 2011 | 106 | 0.170 |
Why?
| | Biological Assay | 2 | 2021 | 112 | 0.170 |
Why?
| | Hot Temperature | 1 | 2021 | 298 | 0.160 |
Why?
| | Exercise Test | 1 | 2022 | 546 | 0.160 |
Why?
| | Ubiquitin-Protein Ligases | 1 | 2020 | 137 | 0.160 |
Why?
| | Collagen Type V | 2 | 2009 | 3 | 0.160 |
Why?
| | Adult | 10 | 2022 | 30245 | 0.160 |
Why?
| | Wnt Signaling Pathway | 1 | 2020 | 145 | 0.160 |
Why?
| | Eosinophils | 1 | 2021 | 273 | 0.160 |
Why?
| | Fatty Acids | 1 | 2022 | 380 | 0.160 |
Why?
| | Mannose-Binding Protein-Associated Serine Proteases | 1 | 2019 | 17 | 0.160 |
Why?
| | Intercellular Signaling Peptides and Proteins | 1 | 2020 | 344 | 0.160 |
Why?
| | beta Catenin | 1 | 2020 | 208 | 0.160 |
Why?
| | Serine C-Palmitoyltransferase | 3 | 2008 | 7 | 0.160 |
Why?
| | Paclitaxel | 2 | 2014 | 187 | 0.160 |
Why?
| | Cell Survival | 3 | 2018 | 1004 | 0.160 |
Why?
| | Oxygen | 2 | 2014 | 827 | 0.160 |
Why?
| | Receptors, Tumor Necrosis Factor | 2 | 2013 | 137 | 0.150 |
Why?
| | Antineoplastic Agents, Phytogenic | 2 | 2014 | 180 | 0.150 |
Why?
| | Databases, Chemical | 1 | 2018 | 6 | 0.150 |
Why?
| | Benzylamines | 1 | 2018 | 39 | 0.150 |
Why?
| | Parenchymal Tissue | 1 | 2018 | 6 | 0.150 |
Why?
| | Estrogen Receptor beta | 1 | 2018 | 33 | 0.150 |
Why?
| | Imipramine | 1 | 2018 | 12 | 0.150 |
Why?
| | Morphine | 2 | 2009 | 121 | 0.150 |
Why?
| | Mucociliary Clearance | 1 | 2018 | 42 | 0.150 |
Why?
| | Academic Medical Centers | 1 | 2020 | 406 | 0.150 |
Why?
| | Chemokine CXCL12 | 1 | 2018 | 74 | 0.150 |
Why?
| | Gene Expression | 2 | 2021 | 1397 | 0.150 |
Why?
| | Disease Outbreaks | 1 | 2020 | 305 | 0.150 |
Why?
| | Cell Line, Transformed | 1 | 2018 | 132 | 0.150 |
Why?
| | Transcriptome | 3 | 2018 | 719 | 0.150 |
Why?
| | Carbon Monoxide | 1 | 2018 | 62 | 0.140 |
Why?
| | Cell Hypoxia | 4 | 2020 | 220 | 0.140 |
Why?
| | Leukocyte Elastase | 1 | 2017 | 70 | 0.140 |
Why?
| | Neovascularization, Pathologic | 2 | 2012 | 280 | 0.140 |
Why?
| | Adrenal Cortex Hormones | 1 | 2020 | 488 | 0.140 |
Why?
| | Lung Transplantation | 2 | 2009 | 241 | 0.140 |
Why?
| | Time Factors | 3 | 2018 | 6032 | 0.140 |
Why?
| | Protein Binding | 3 | 2018 | 1867 | 0.140 |
Why?
| | Bone Marrow | 1 | 2018 | 242 | 0.140 |
Why?
| | THP-1 Cells | 1 | 2016 | 19 | 0.130 |
Why?
| | High-Intensity Interval Training | 1 | 2016 | 18 | 0.130 |
Why?
| | Spinal Cord | 2 | 2009 | 344 | 0.130 |
Why?
| | Mitogen-Activated Protein Kinases | 2 | 2011 | 262 | 0.130 |
Why?
| | Adipocytes | 1 | 2018 | 185 | 0.130 |
Why?
| | Sleep Apnea Syndromes | 1 | 2017 | 73 | 0.130 |
Why?
| | Neutrophils | 1 | 2021 | 1072 | 0.130 |
Why?
| | Pandemics | 2 | 2021 | 1308 | 0.130 |
Why?
| | Bronchi | 1 | 2017 | 222 | 0.130 |
Why?
| | Aging | 2 | 2021 | 1601 | 0.130 |
Why?
| | Insulin-Secreting Cells | 1 | 2020 | 317 | 0.130 |
Why?
| | Plasma | 1 | 2017 | 180 | 0.130 |
Why?
| | Protein Kinases | 1 | 2018 | 300 | 0.130 |
Why?
| | Delivery of Health Care | 1 | 2022 | 828 | 0.130 |
Why?
| | Actins | 3 | 2018 | 373 | 0.120 |
Why?
| | Mesenchymal Stem Cell Transplantation | 1 | 2015 | 37 | 0.120 |
Why?
| | Monocrotaline | 1 | 2015 | 26 | 0.120 |
Why?
| | Mice, 129 Strain | 2 | 2012 | 77 | 0.120 |
Why?
| | I-kappa B Proteins | 2 | 2013 | 75 | 0.120 |
Why?
| | Ventricular Pressure | 1 | 2015 | 39 | 0.120 |
Why?
| | Hematopoietic Stem Cells | 1 | 2018 | 337 | 0.120 |
Why?
| | Myelopoiesis | 1 | 2015 | 6 | 0.120 |
Why?
| | Binding, Competitive | 1 | 2015 | 192 | 0.120 |
Why?
| | Glycosphingolipids | 1 | 2015 | 8 | 0.120 |
Why?
| | Severity of Illness Index | 2 | 2020 | 2530 | 0.120 |
Why?
| | Cathepsin E | 1 | 2014 | 1 | 0.120 |
Why?
| | Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2015 | 131 | 0.120 |
Why?
| | Cell Membrane Permeability | 1 | 2015 | 81 | 0.120 |
Why?
| | Culture Media, Conditioned | 1 | 2015 | 103 | 0.120 |
Why?
| | Collagen Type VI | 1 | 2014 | 3 | 0.120 |
Why?
| | Immunoblotting | 1 | 2015 | 277 | 0.120 |
Why?
| | Arterial Pressure | 1 | 2015 | 98 | 0.120 |
Why?
| | Hexuronic Acids | 1 | 2014 | 23 | 0.120 |
Why?
| | Asthma | 2 | 2020 | 2016 | 0.120 |
Why?
| | Glucuronic Acid | 1 | 2014 | 25 | 0.120 |
Why?
| | Mitochondrial Dynamics | 1 | 2014 | 22 | 0.120 |
Why?
| | Polysaccharide-Lyases | 1 | 2014 | 11 | 0.120 |
Why?
| | United States | 4 | 2024 | 12137 | 0.120 |
Why?
| | Intracellular Signaling Peptides and Proteins | 2 | 2010 | 382 | 0.120 |
Why?
| | Nitric Oxide Synthase Type III | 1 | 2015 | 181 | 0.120 |
Why?
| | Mice, Inbred C3H | 1 | 2014 | 242 | 0.110 |
Why?
| | Metabolome | 1 | 2017 | 275 | 0.110 |
Why?
| | HIV Infections | 3 | 2017 | 2440 | 0.110 |
Why?
| | Propylene Glycols | 2 | 2014 | 25 | 0.110 |
Why?
| | Membrane Potential, Mitochondrial | 1 | 2014 | 55 | 0.110 |
Why?
| | Glycolysis | 1 | 2015 | 223 | 0.110 |
Why?
| | Dehydroepiandrosterone | 1 | 2014 | 49 | 0.110 |
Why?
| | Ligands | 3 | 2023 | 553 | 0.110 |
Why?
| | Ventricular Dysfunction, Right | 1 | 2016 | 216 | 0.110 |
Why?
| | Hyperoxia | 1 | 2015 | 97 | 0.110 |
Why?
| | Ventricular Remodeling | 2 | 2015 | 221 | 0.110 |
Why?
| | HMGB1 Protein | 1 | 2014 | 47 | 0.110 |
Why?
| | Paracrine Communication | 1 | 2014 | 55 | 0.110 |
Why?
| | Oligopeptides | 2 | 2014 | 231 | 0.110 |
Why?
| | HIV Envelope Protein gp120 | 1 | 2013 | 55 | 0.110 |
Why?
| | Predictive Value of Tests | 2 | 2015 | 1783 | 0.110 |
Why?
| | NF-KappaB Inhibitor alpha | 1 | 2013 | 48 | 0.110 |
Why?
| | Familial Primary Pulmonary Hypertension | 1 | 2014 | 190 | 0.110 |
Why?
| | Virulence | 1 | 2014 | 228 | 0.110 |
Why?
| | Smoking Cessation | 1 | 2017 | 373 | 0.110 |
Why?
| | Apoptosis Regulatory Proteins | 1 | 2014 | 168 | 0.110 |
Why?
| | Calpain | 1 | 2013 | 53 | 0.110 |
Why?
| | Cross-Sectional Studies | 1 | 2023 | 4400 | 0.110 |
Why?
| | MAP Kinase Signaling System | 2 | 2012 | 267 | 0.110 |
Why?
| | Ventricular Function, Right | 1 | 2015 | 251 | 0.110 |
Why?
| | Glycerylphosphorylcholine | 1 | 2013 | 5 | 0.110 |
Why?
| | Vascular Endothelial Growth Factor A | 2 | 2006 | 496 | 0.110 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2020 | 1856 | 0.110 |
Why?
| | Platelet Membrane Glycoproteins | 1 | 2013 | 32 | 0.100 |
Why?
| | Bronchitis, Chronic | 1 | 2013 | 17 | 0.100 |
Why?
| | Dermatitis, Contact | 1 | 2013 | 23 | 0.100 |
Why?
| | Platelet Activating Factor | 1 | 2013 | 69 | 0.100 |
Why?
| | Cattle | 3 | 2008 | 913 | 0.100 |
Why?
| | Liposomes | 1 | 2014 | 143 | 0.100 |
Why?
| | Proteolysis | 1 | 2013 | 141 | 0.100 |
Why?
| | Neuralgia | 1 | 2014 | 122 | 0.100 |
Why?
| | Adaptor Proteins, Vesicular Transport | 1 | 2013 | 44 | 0.100 |
Why?
| | Risk Factors | 4 | 2020 | 8606 | 0.100 |
Why?
| | Lung Compliance | 1 | 2012 | 46 | 0.100 |
Why?
| | Drug Tolerance | 2 | 2009 | 77 | 0.100 |
Why?
| | Estrogen Antagonists | 1 | 2012 | 39 | 0.100 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p27 | 1 | 2012 | 68 | 0.100 |
Why?
| | Analgesics, Opioid | 2 | 2009 | 770 | 0.100 |
Why?
| | Proto-Oncogene Proteins c-akt | 1 | 2014 | 394 | 0.100 |
Why?
| | Airway Remodeling | 1 | 2012 | 57 | 0.100 |
Why?
| | Aged | 5 | 2020 | 18944 | 0.100 |
Why?
| | Cardiac Output | 1 | 2012 | 139 | 0.100 |
Why?
| | Exercise | 1 | 2022 | 1617 | 0.100 |
Why?
| | Atmosphere Exposure Chambers | 1 | 2011 | 4 | 0.090 |
Why?
| | Polymerase Chain Reaction | 2 | 2015 | 984 | 0.090 |
Why?
| | Analysis of Variance | 1 | 2014 | 1208 | 0.090 |
Why?
| | Catalase | 1 | 2011 | 118 | 0.090 |
Why?
| | Bronchioles | 1 | 2011 | 22 | 0.090 |
Why?
| | Microcirculation | 1 | 2011 | 130 | 0.090 |
Why?
| | Goblet Cells | 1 | 2011 | 16 | 0.090 |
Why?
| | Receptors, G-Protein-Coupled | 1 | 2013 | 182 | 0.090 |
Why?
| | Tetradecanoylphorbol Acetate | 1 | 2011 | 145 | 0.090 |
Why?
| | Permeability | 1 | 2011 | 144 | 0.090 |
Why?
| | Immunization, Passive | 1 | 2011 | 72 | 0.090 |
Why?
| | Inflammasomes | 1 | 2012 | 115 | 0.090 |
Why?
| | Interleukin-1beta | 1 | 2013 | 364 | 0.090 |
Why?
| | Phosphorylation | 1 | 2015 | 1537 | 0.090 |
Why?
| | Ceramidases | 1 | 2010 | 4 | 0.090 |
Why?
| | Testosterone | 1 | 2014 | 341 | 0.090 |
Why?
| | Plant Extracts | 1 | 2012 | 154 | 0.090 |
Why?
| | Perfusion | 1 | 2011 | 147 | 0.090 |
Why?
| | Carcinogens | 1 | 2011 | 101 | 0.090 |
Why?
| | Stem Cells | 1 | 2015 | 538 | 0.090 |
Why?
| | Acetylcysteine | 1 | 2011 | 141 | 0.090 |
Why?
| | Jurkat Cells | 1 | 2010 | 122 | 0.090 |
Why?
| | Mice, Inbred Strains | 1 | 2011 | 394 | 0.090 |
Why?
| | rac1 GTP-Binding Protein | 1 | 2010 | 53 | 0.090 |
Why?
| | Adaptation, Physiological | 1 | 2014 | 465 | 0.090 |
Why?
| | RNA, Messenger | 1 | 2017 | 2507 | 0.090 |
Why?
| | Biosensing Techniques | 1 | 2011 | 100 | 0.090 |
Why?
| | Myocardium | 1 | 2015 | 906 | 0.090 |
Why?
| | Transplantation, Heterologous | 1 | 2010 | 180 | 0.090 |
Why?
| | Mutation | 1 | 2020 | 3313 | 0.090 |
Why?
| | Oxidation-Reduction | 3 | 2022 | 912 | 0.080 |
Why?
| | Cell Line, Tumor | 3 | 2011 | 2690 | 0.080 |
Why?
| | Phosphotransferases (Alcohol Group Acceptor) | 1 | 2009 | 41 | 0.080 |
Why?
| | Adaptor Proteins, Signal Transducing | 1 | 2012 | 367 | 0.080 |
Why?
| | Immunosuppressive Agents | 2 | 2014 | 633 | 0.080 |
Why?
| | Posterior Horn Cells | 1 | 2009 | 4 | 0.080 |
Why?
| | Software | 1 | 2013 | 525 | 0.080 |
Why?
| | Pulmonary Circulation | 1 | 2011 | 400 | 0.080 |
Why?
| | Immunohistochemistry | 4 | 2011 | 1604 | 0.080 |
Why?
| | Transplantation Tolerance | 1 | 2009 | 30 | 0.080 |
Why?
| | Peptide Fragments | 1 | 2013 | 652 | 0.080 |
Why?
| | Clathrin | 1 | 2009 | 24 | 0.080 |
Why?
| | Transcription, Genetic | 2 | 2013 | 1282 | 0.080 |
Why?
| | Bronchoalveolar Lavage | 3 | 2018 | 82 | 0.080 |
Why?
| | Heart Ventricles | 1 | 2014 | 710 | 0.080 |
Why?
| | Transplantation, Homologous | 1 | 2010 | 373 | 0.080 |
Why?
| | NF-E2-Related Factor 2 | 2 | 2006 | 71 | 0.080 |
Why?
| | Peroxynitrous Acid | 1 | 2008 | 11 | 0.080 |
Why?
| | Sex Factors | 1 | 2014 | 1705 | 0.080 |
Why?
| | Immunity, Innate | 1 | 2014 | 716 | 0.080 |
Why?
| | Obesity | 2 | 2020 | 2501 | 0.080 |
Why?
| | Cyclosporine | 1 | 2009 | 160 | 0.080 |
Why?
| | Protein Precursors | 1 | 2009 | 118 | 0.080 |
Why?
| | Histocompatibility Antigens | 1 | 2009 | 98 | 0.080 |
Why?
| | Pyrroles | 1 | 2009 | 179 | 0.080 |
Why?
| | Superoxide Dismutase-1 | 1 | 2008 | 8 | 0.080 |
Why?
| | Myocytes, Smooth Muscle | 2 | 2020 | 235 | 0.080 |
Why?
| | p38 Mitogen-Activated Protein Kinases | 2 | 2013 | 244 | 0.080 |
Why?
| | Neoplasms, Glandular and Epithelial | 1 | 2008 | 34 | 0.080 |
Why?
| | Glycerophospholipids | 2 | 2018 | 26 | 0.070 |
Why?
| | Patch-Clamp Techniques | 1 | 2009 | 236 | 0.070 |
Why?
| | Transglutaminases | 1 | 2008 | 142 | 0.070 |
Why?
| | Diabetes Mellitus, Type 2 | 2 | 2020 | 2088 | 0.070 |
Why?
| | Histocompatibility Antigens Class II | 1 | 2009 | 349 | 0.070 |
Why?
| | Hypersensitivity | 1 | 2011 | 251 | 0.070 |
Why?
| | Caspase 9 | 2 | 2008 | 47 | 0.070 |
Why?
| | Indoles | 1 | 2009 | 296 | 0.070 |
Why?
| | Superoxides | 1 | 2008 | 186 | 0.070 |
Why?
| | Hydrogen Peroxide | 1 | 2009 | 287 | 0.070 |
Why?
| | Antiviral Agents | 2 | 2023 | 635 | 0.070 |
Why?
| | Antibody Formation | 1 | 2008 | 265 | 0.070 |
Why?
| | Organ Size | 1 | 2008 | 420 | 0.070 |
Why?
| | Cisplatin | 1 | 2008 | 261 | 0.070 |
Why?
| | Cell-Free System | 1 | 2006 | 45 | 0.070 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 1 | 2014 | 953 | 0.070 |
Why?
| | Capillaries | 1 | 2006 | 90 | 0.070 |
Why?
| | Muscle, Skeletal | 1 | 2015 | 1417 | 0.070 |
Why?
| | Graft Rejection | 1 | 2009 | 508 | 0.060 |
Why?
| | Antigens, CD | 2 | 2011 | 437 | 0.060 |
Why?
| | Weight Loss | 1 | 2010 | 640 | 0.060 |
Why?
| | Blood Pressure | 1 | 2012 | 1521 | 0.060 |
Why?
| | Disease Progression | 1 | 2012 | 2364 | 0.060 |
Why?
| | Fumonisins | 1 | 2005 | 3 | 0.060 |
Why?
| | Adenoviridae | 1 | 2006 | 179 | 0.060 |
Why?
| | Regeneration | 1 | 2006 | 158 | 0.060 |
Why?
| | Acyltransferases | 1 | 2005 | 46 | 0.060 |
Why?
| | Fatty Acids, Monounsaturated | 1 | 2005 | 47 | 0.060 |
Why?
| | Deoxyguanosine | 1 | 2004 | 26 | 0.060 |
Why?
| | Immunoglobulin G | 1 | 2008 | 760 | 0.060 |
Why?
| | CX3C Chemokine Receptor 1 | 1 | 2023 | 17 | 0.060 |
Why?
| | Ovarian Neoplasms | 1 | 2008 | 386 | 0.050 |
Why?
| | Supreme Court Decisions | 1 | 2023 | 10 | 0.050 |
Why?
| | Stress Fibers | 1 | 2003 | 16 | 0.050 |
Why?
| | Receptors, Tumor Necrosis Factor, Type I | 1 | 2003 | 68 | 0.050 |
Why?
| | Adherens Junctions | 1 | 2003 | 26 | 0.050 |
Why?
| | Caspase 8 | 1 | 2003 | 43 | 0.050 |
Why?
| | Antibodies, Monoclonal | 1 | 2009 | 1236 | 0.050 |
Why?
| | Myosins | 1 | 2003 | 123 | 0.050 |
Why?
| | rho-Associated Kinases | 1 | 2003 | 80 | 0.050 |
Why?
| | Sphingomyelins | 2 | 2015 | 26 | 0.050 |
Why?
| | Trans-Activators | 1 | 2004 | 356 | 0.050 |
Why?
| | Lung Neoplasms | 1 | 2014 | 2148 | 0.050 |
Why?
| | Imidazoles | 1 | 2003 | 203 | 0.050 |
Why?
| | Cell Communication | 1 | 2023 | 274 | 0.050 |
Why?
| | Receptors, Cell Surface | 1 | 2023 | 347 | 0.050 |
Why?
| | Epithelium | 1 | 2022 | 293 | 0.050 |
Why?
| | Antineoplastic Agents | 2 | 2009 | 1872 | 0.050 |
Why?
| | Autophagosomes | 1 | 2021 | 19 | 0.050 |
Why?
| | Autoantibodies | 1 | 2008 | 1349 | 0.050 |
Why?
| | Neurons | 1 | 2008 | 1261 | 0.050 |
Why?
| | Autophagy-Related Proteins | 1 | 2021 | 39 | 0.040 |
Why?
| | Fever | 1 | 2022 | 266 | 0.040 |
Why?
| | Gene Knockout Techniques | 1 | 2020 | 98 | 0.040 |
Why?
| | Hyaluronoglucosaminidase | 1 | 2020 | 9 | 0.040 |
Why?
| | Transcription Factor RelA | 1 | 2020 | 75 | 0.040 |
Why?
| | Pyridines | 1 | 2003 | 417 | 0.040 |
Why?
| | Cohort Studies | 2 | 2020 | 4880 | 0.040 |
Why?
| | Propensity Score | 1 | 2020 | 225 | 0.040 |
Why?
| | Endoplasmic Reticulum Stress | 1 | 2020 | 91 | 0.040 |
Why?
| | Carrier Proteins | 1 | 2023 | 685 | 0.040 |
Why?
| | Oligonucleotide Array Sequence Analysis | 2 | 2016 | 739 | 0.040 |
Why?
| | Rats, Inbred WKY | 2 | 2009 | 32 | 0.040 |
Why?
| | Administration, Inhalation | 1 | 2020 | 633 | 0.040 |
Why?
| | Swine | 1 | 2021 | 687 | 0.040 |
Why?
| | Lipid Metabolism | 1 | 2022 | 438 | 0.040 |
Why?
| | Cell Lineage | 1 | 2020 | 305 | 0.040 |
Why?
| | Glucose Tolerance Test | 1 | 2020 | 338 | 0.040 |
Why?
| | Diet, High-Fat | 1 | 2020 | 224 | 0.040 |
Why?
| | Procollagen-Proline Dioxygenase | 1 | 2018 | 26 | 0.040 |
Why?
| | Hypoxia-Inducible Factor-Proline Dioxygenases | 1 | 2018 | 20 | 0.040 |
Why?
| | Propionates | 1 | 2018 | 33 | 0.040 |
Why?
| | Proteomics | 1 | 2023 | 808 | 0.040 |
Why?
| | Odds Ratio | 1 | 2020 | 953 | 0.040 |
Why?
| | Vital Capacity | 1 | 2018 | 249 | 0.040 |
Why?
| | Protein Stability | 1 | 2018 | 156 | 0.040 |
Why?
| | Nitriles | 1 | 2018 | 149 | 0.040 |
Why?
| | Genome-Wide Association Study | 1 | 2023 | 1157 | 0.040 |
Why?
| | Betacoronavirus | 1 | 2020 | 246 | 0.040 |
Why?
| | RNA | 1 | 2023 | 801 | 0.040 |
Why?
| | Referral and Consultation | 1 | 2022 | 632 | 0.040 |
Why?
| | Estrogen Receptor alpha | 1 | 2018 | 121 | 0.040 |
Why?
| | Sample Size | 1 | 2017 | 107 | 0.030 |
Why?
| | Weight Gain | 1 | 2020 | 454 | 0.030 |
Why?
| | HIV | 1 | 2017 | 205 | 0.030 |
Why?
| | Basic Helix-Loop-Helix Transcription Factors | 1 | 2018 | 222 | 0.030 |
Why?
| | Young Adult | 1 | 2011 | 10400 | 0.030 |
Why?
| | Chronic Disease | 1 | 2022 | 1570 | 0.030 |
Why?
| | Pulmonary Gas Exchange | 1 | 2016 | 105 | 0.030 |
Why?
| | Logistic Models | 1 | 2020 | 1832 | 0.030 |
Why?
| | Antioxidants | 2 | 2013 | 527 | 0.030 |
Why?
| | NF-kappa B | 2 | 2010 | 615 | 0.030 |
Why?
| | Retrospective Studies | 2 | 2022 | 12504 | 0.030 |
Why?
| | Physical Endurance | 1 | 2016 | 228 | 0.030 |
Why?
| | Pneumonia, Viral | 1 | 2020 | 333 | 0.030 |
Why?
| | Coronavirus Infections | 1 | 2020 | 325 | 0.030 |
Why?
| | Cell- and Tissue-Based Therapy | 1 | 2015 | 53 | 0.030 |
Why?
| | Trihexosylceramides | 1 | 2015 | 4 | 0.030 |
Why?
| | Administration, Intravenous | 1 | 2015 | 122 | 0.030 |
Why?
| | Glucose | 1 | 2020 | 894 | 0.030 |
Why?
| | E-Selectin | 1 | 2015 | 52 | 0.030 |
Why?
| | Tandem Mass Spectrometry | 1 | 2017 | 405 | 0.030 |
Why?
| | Interleukin-23 Subunit p19 | 1 | 2014 | 5 | 0.030 |
Why?
| | Neutrophil Infiltration | 1 | 2015 | 94 | 0.030 |
Why?
| | Quinazolinones | 1 | 2014 | 19 | 0.030 |
Why?
| | Physical Conditioning, Animal | 1 | 2016 | 187 | 0.030 |
Why?
| | Indans | 1 | 2014 | 9 | 0.030 |
Why?
| | Heterografts | 1 | 2015 | 117 | 0.030 |
Why?
| | Oxadiazoles | 1 | 2014 | 32 | 0.030 |
Why?
| | Respiratory Function Tests | 1 | 2016 | 517 | 0.030 |
Why?
| | Intercellular Adhesion Molecule-1 | 1 | 2015 | 145 | 0.030 |
Why?
| | Leukocyte Count | 1 | 2015 | 291 | 0.030 |
Why?
| | Pilot Projects | 1 | 2018 | 1356 | 0.030 |
Why?
| | Mice, SCID | 1 | 2015 | 311 | 0.030 |
Why?
| | Anilides | 1 | 2014 | 67 | 0.030 |
Why?
| | Islets of Langerhans | 1 | 2020 | 728 | 0.030 |
Why?
| | Thiazoles | 1 | 2014 | 109 | 0.030 |
Why?
| | Organophosphonates | 1 | 2014 | 88 | 0.030 |
Why?
| | Cricetulus | 1 | 2013 | 96 | 0.030 |
Why?
| | CHO Cells | 1 | 2013 | 135 | 0.030 |
Why?
| | Phosphatidylserines | 1 | 2014 | 80 | 0.030 |
Why?
| | Thiophenes | 1 | 2014 | 108 | 0.030 |
Why?
| | Cricetinae | 1 | 2013 | 244 | 0.030 |
Why?
| | Dinitrofluorobenzene | 1 | 2013 | 7 | 0.030 |
Why?
| | Phosphatidylcholines | 1 | 2014 | 132 | 0.030 |
Why?
| | Mice, Inbred NOD | 1 | 2015 | 551 | 0.030 |
Why?
| | Cyclooxygenase 2 Inhibitors | 1 | 2013 | 20 | 0.030 |
Why?
| | Lipid Bilayers | 1 | 2014 | 94 | 0.030 |
Why?
| | Culture Media, Serum-Free | 1 | 2012 | 42 | 0.030 |
Why?
| | Animals, Newborn | 1 | 2015 | 769 | 0.030 |
Why?
| | Lymphocyte Depletion | 1 | 2013 | 115 | 0.030 |
Why?
| | Lipid Peroxidation | 1 | 2013 | 138 | 0.030 |
Why?
| | Hydrolases | 1 | 2013 | 51 | 0.030 |
Why?
| | Chemokine CXCL10 | 1 | 2012 | 32 | 0.030 |
Why?
| | Leukocytes, Mononuclear | 1 | 2015 | 487 | 0.020 |
Why?
| | Cyclooxygenase 2 | 1 | 2013 | 161 | 0.020 |
Why?
| | Inflammation Mediators | 1 | 2015 | 469 | 0.020 |
Why?
| | Insulin Resistance | 1 | 2020 | 1068 | 0.020 |
Why?
| | Forkhead Transcription Factors | 1 | 2013 | 169 | 0.020 |
Why?
| | Gene Knockdown Techniques | 1 | 2013 | 298 | 0.020 |
Why?
| | Tyrosine | 1 | 2012 | 203 | 0.020 |
Why?
| | Computer Simulation | 1 | 2016 | 858 | 0.020 |
Why?
| | Metaplasia | 1 | 2011 | 54 | 0.020 |
Why?
| | Blood Glucose | 1 | 2020 | 1823 | 0.020 |
Why?
| | Extracellular Matrix | 1 | 2014 | 433 | 0.020 |
Why?
| | Mucus | 1 | 2011 | 54 | 0.020 |
Why?
| | Sensitivity and Specificity | 1 | 2015 | 1682 | 0.020 |
Why?
| | Insulin | 1 | 2020 | 2076 | 0.020 |
Why?
| | T-Lymphocytes, Regulatory | 1 | 2013 | 337 | 0.020 |
Why?
| | Th2 Cells | 1 | 2011 | 154 | 0.020 |
Why?
| | Rats, Inbred Lew | 1 | 2009 | 86 | 0.020 |
Why?
| | Rats, Inbred BN | 1 | 2009 | 51 | 0.020 |
Why?
| | Dose-Response Relationship, Immunologic | 1 | 2009 | 73 | 0.020 |
Why?
| | Histocompatibility Testing | 1 | 2009 | 114 | 0.020 |
Why?
| | Spleen | 1 | 2011 | 480 | 0.020 |
Why?
| | Transplantation, Isogeneic | 1 | 2008 | 17 | 0.020 |
Why?
| | Coculture Techniques | 1 | 2009 | 198 | 0.020 |
Why?
| | Databases, Factual | 1 | 2013 | 1127 | 0.020 |
Why?
| | X-Linked Inhibitor of Apoptosis Protein | 1 | 2008 | 11 | 0.020 |
Why?
| | Glial Fibrillary Acidic Protein | 1 | 2008 | 78 | 0.020 |
Why?
| | Isoxazoles | 1 | 2008 | 51 | 0.020 |
Why?
| | GTP-Binding Proteins | 1 | 2008 | 138 | 0.020 |
Why?
| | Aged, 80 and over | 1 | 2018 | 6296 | 0.020 |
Why?
| | Administration, Oral | 1 | 2009 | 719 | 0.020 |
Why?
| | Xenograft Model Antitumor Assays | 1 | 2009 | 693 | 0.020 |
Why?
| | Algorithms | 1 | 2013 | 1462 | 0.020 |
Why?
| | Drug Therapy, Combination | 1 | 2009 | 944 | 0.020 |
Why?
| | Postural Balance | 1 | 2008 | 185 | 0.020 |
Why?
| | Pleura | 1 | 2005 | 18 | 0.020 |
Why?
| | Ligation | 1 | 2005 | 74 | 0.020 |
Why?
| | In Situ Nick-End Labeling | 1 | 2004 | 117 | 0.010 |
Why?
| | Mice, Inbred ICR | 1 | 2004 | 108 | 0.010 |
Why?
| | B-Lymphocytes | 1 | 2008 | 757 | 0.010 |
Why?
| | Pulmonary Embolism | 1 | 2005 | 181 | 0.010 |
Why?
| | T-Lymphocytes | 1 | 2011 | 1725 | 0.010 |
Why?
| | Peptides | 1 | 2008 | 844 | 0.010 |
Why?
| | Treatment Outcome | 1 | 2016 | 9006 | 0.010 |
Why?
| | Endopeptidases | 1 | 2003 | 70 | 0.010 |
Why?
| | Microscopy, Fluorescence | 1 | 2004 | 386 | 0.010 |
Why?
| | Models, Biological | 1 | 2008 | 1589 | 0.010 |
Why?
| | Child | 1 | 2017 | 18340 | 0.010 |
Why?
|
|
Petrache's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|